Procter & Gamble Health Limited
Procter & Gamble Health Limited Fundamental Analysis
Procter & Gamble Health Limited (PGHL.BO) shows moderate financial fundamentals with a PE ratio of 29.05, profit margin of 21.76%, and ROE of 50.95%. The company generates $13.5B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 99.8/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze PGHL.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentPGHL.BO demonstrates superior asset utilization.
Valuation Score
ModeratePGHL.BO shows balanced valuation metrics.
Growth Score
ModeratePGHL.BO shows steady but slowing expansion.
Financial Health Score
ExcellentPGHL.BO maintains a strong and stable balance sheet.
Profitability Score
ExcellentPGHL.BO achieves industry-leading margins.
Key Financial Metrics
Is PGHL.BO Expensive or Cheap?
P/E Ratio
PGHL.BO trades at 29.05 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PGHL.BO's PEG of -6.69 indicates potential undervaluation.
Price to Book
The market values Procter & Gamble Health Limited at 13.76 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 21.40 times EBITDA. This signals the market has high growth expectations.
How Well Does PGHL.BO Make Money?
Net Profit Margin
For every $100 in sales, Procter & Gamble Health Limited keeps $21.76 as profit after all expenses.
Operating Margin
Core operations generate 42.34 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $50.95 in profit for every $100 of shareholder equity.
ROA
Procter & Gamble Health Limited generates $32.81 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Procter & Gamble Health Limited generates limited operating cash flow of $492.20M, signaling weaker underlying cash strength.
Free Cash Flow
Procter & Gamble Health Limited produces free cash flow of $459.90M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $27.71 in free cash annually.
FCF Yield
PGHL.BO converts 0.54% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.05
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-6.69
vs 25 benchmark
P/B Ratio
Price to book value ratio
13.76
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.32
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.87
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.51
vs 25 benchmark
ROA
Return on assets percentage
0.33
vs 25 benchmark
ROCE
Return on capital employed
0.85
vs 25 benchmark
How PGHL.BO Stacks Against Its Sector Peers
| Metric | PGHL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.05 | 29.45 | Neutral |
| ROE | 50.95% | 779.00% | Weak |
| Net Margin | 21.76% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 2.87 | 4.65 | Strong Liquidity |
| ROA | 32.81% | -19344.00% (disorted) | Strong |
PGHL.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Procter & Gamble Health Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation